Personal Capital Advisors Corp acquired a new position in Core Laboratories (NYSE:CLB) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 3,234 shares of the oil and gas company’s stock, valued at approximately $375,000.
Several other hedge funds have also bought and sold shares of CLB. WCM Investment Management CA raised its position in shares of Core Laboratories by 5.0% in the 2nd quarter. WCM Investment Management CA now owns 5,285,156 shares of the oil and gas company’s stock worth $667,040,000 after acquiring an additional 249,329 shares in the last quarter. Millennium Management LLC increased its position in Core Laboratories by 9,329.6% in the 2nd quarter. Millennium Management LLC now owns 226,594 shares of the oil and gas company’s stock valued at $28,598,000 after buying an additional 224,191 shares in the last quarter. Select Equity Group L.P. increased its position in Core Laboratories by 68.5% in the 1st quarter. Select Equity Group L.P. now owns 299,467 shares of the oil and gas company’s stock valued at $32,408,000 after buying an additional 121,786 shares in the last quarter. BlackRock Inc. increased its position in Core Laboratories by 3.8% in the 2nd quarter. BlackRock Inc. now owns 3,186,363 shares of the oil and gas company’s stock valued at $402,151,000 after buying an additional 117,678 shares in the last quarter. Finally, Segall Bryant & Hamill LLC bought a new stake in Core Laboratories in the 2nd quarter valued at about $8,084,000.
A number of brokerages recently commented on CLB. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $96.00 target price on shares of Core Laboratories in a research report on Friday, July 27th. Zacks Investment Research raised Core Laboratories from a “sell” rating to a “hold” rating in a research report on Friday. JPMorgan Chase & Co. decreased their target price on Core Laboratories from $121.00 to $118.00 and set an “overweight” rating for the company in a research report on Friday, July 27th. ValuEngine raised Core Laboratories from a “hold” rating to a “buy” rating in a research report on Wednesday, September 26th. Finally, Citigroup lowered Core Laboratories from a “neutral” rating to a “sell” rating in a research report on Monday, July 2nd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $115.15.
CLB stock opened at $107.25 on Friday. The stock has a market cap of $5.12 billion, a price-to-earnings ratio of 53.29, a P/E/G ratio of 3.96 and a beta of 1.46. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.24 and a quick ratio of 1.85. Core Laboratories has a 52-week low of $87.66 and a 52-week high of $130.34.
Core Laboratories (NYSE:CLB) last released its quarterly earnings results on Wednesday, July 25th. The oil and gas company reported $0.59 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.59. The business had revenue of $175.48 million during the quarter, compared to the consensus estimate of $174.47 million. Core Laboratories had a return on equity of 64.13% and a net margin of 13.32%. The company’s quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.51 EPS. On average, analysts forecast that Core Laboratories will post 2.44 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 20th. Shareholders of record on Friday, October 19th will be paid a dividend of $0.55 per share. The ex-dividend date of this dividend is Thursday, October 18th. This represents a $2.20 dividend on an annualized basis and a yield of 2.05%. Core Laboratories’s dividend payout ratio (DPR) is currently 110.00%.
About Core Laboratories
Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.
Read More: Stock Symbols Definition, Examples, Lookup
Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).
Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.